Main > A1. CORP. INDEX. E-Em > Eli Lilly./P C2
This data is not available for free
Eli Lilly./P C2's subsections
1998. 05.15.1998. (PhytoSterol)
2000. 01.17.2000. (Diabetes)
2000. 01.17.2000. (Patent Expir.)
2000. 03.06.2000. (Antibiotics)
2000. 03.15.2000. (Psychiatry)
2000. 04.24.2000. (Antibiotics)
2000. 05.09.2000. (Psychiatry)
2000. 07.11.2000. (Gynecology)
2000. 08.14.2000. (Psychiatry)
2000. 08.28.2000. (Osteoporosis)
2000. 10.23.2000. (Psychiatry)
2000. 10.26.2000. (Psychiatry)
2000. 10.30.2000. (Psychiatry)
2001. 03.19.2001. (Alliance)
2001. 04.01.2001. (Impotence)
2001. 04.02.2001. (License)
2001. 04.30.2001. (Diabetes)
2001. 05.09.2001. (Psychiatry)
2001. 05.11.2001. (Osteoporosis)
2001. 05.14.2001. (Diabetes)
2001. 05.22.2001. (Patent Expir.)
2001. 06.15.2001. (Impotence)
2001. 08.06.2001. (R&D Agreement)
2001. 08.27.2001. (Oncology)
2001. 08.29.2001. (Psychiatry)
2001. 09.24.2001. (Oncology)
2001. 11.23.2001. (Septicemia)
2002. 01.26.2002. (Impotence)
2002. 03.25.2002. (Partnership)
2002. 04.08.2002. (Impotence)
2002. 04.08.2002. (NMR)
2002. 04.08.2002. (Proteomics)
2002. 04.29.2002. (Prion Diag.)
2002. 05.20.2002. (Accelrys Deal)
2002. 05.27.2002. (Diabetes)
2002. 06.17.2002. (Diabetes)
2002. 06.24.2002. (Oncology)
2002. 07.01.2002. (Legal Dispute)
2002. 07.22.2002. (Diabetes)
2002. 09.09.2002. (Chiral Organics)
2002. 09.23.2002. (Against Generic)
2002. 09.23.2002. (Patent Expir.)
2002. 09.23.2002. (Psychiatry)
2002. 09.30.2002. (Diabetes)
2002. 09.30.2002. (GH)
2002. 10.07.2002. (Oncology)
2002. 10.14.2002. (Alliance)
2002. 11.04.2002. (Licensor of)
2002. 11.11.2002. (Member of)
2002. 11.11.2002. (Process Chem.)
2002. 11.18.2002. (Supplier)
2002. 12.02.2002. (Diabetes)
2002. 12.02.2002. (Metabonomics)
2002. 12.02.2002. (Neuro>Schizophr)
2002. 12.02.2002. (Osteoporosis)
2002. 12.02.2002. (Psychiatry)
2002. 12.02.2002. (Septicemia)
2003. 01.06.2003. (Cooperation)
2003. 02.03.2003. (Cooperation)
2003. 02.24.2003. (AMRI R&D Deal)
2003. 03.17.2003. (Osteoporosis)
2003. 03.31.2003. (AME Coop.)
2003. 04.07.2003. (Oncology)
2003. 04.28.2003. (Gene/Structure)
2003. 04.28.2003. (Oncology)
2003. 05.19.2003. (Polymorphism)
2003. 06.30.2003. (AME Coop.)
2003. 12.01.2003. (Executive)
2003. 12.01.2003. (Parent of)
2004. 08.02.2004. (TransForm..)
2004. 08.09.2004. (Drug Safety)
2004. 11.22.2004. (Metab Syndrome)
2005. 03.24.2005. (Diabetes)
2005. 09.05.2005. (SFC)
2006. 01.09.2006. (Jubilant Organo)
2006. 01.09.2006. (Osteoporosis)
2006. 08.28.2006. Exec VP Science
2007. 01.22.2007. Global Ext. R&D
2007. 03.26.2007. Tuberculosis
2007. 04.02.2007. Singapore
2007. 05.14.2007. Exec VP Science &
2007. 05.28.2007. TB>Cycloserine
2007. 06.18.2007. TB Center
2007. 08.06.2007. Research Adviser
2007. 08.27.2007. (Hutchison Medi)
2007. 08.27.2007. Research Adviser
2007. 09.25.2007. (Oncology)
2007. 10.08.2007. (Oncology>Diag)
2007. 11.04.2007. (Cardiology)
2007. 11.05.2007. (Glenmark Pharma)
2007. 12.03.2007. (VP Project &)
2007. 12.17.2007. (Neuro.>MS)
2007. 12.19.2007. (Osteoporosis)
2008. 01.04.2008. (Cardiology) >
2008. 01.08.2008. Uro.>ED
2008. 02.20.2008. (Cardiology)
2008. 02.22.2008. (Osteoporosis)
2008. 02.28.2008. (Neuro>Schizophr)
2008. 03.07.2008. (Diabetes)
2008. 03.13.2008. (Diabetes)
2008. 03.17.2008. (Chairman & CEO)
2008. 03.29.2008. (Cardiology)
2008. 03.31.2008. (Neuro>AD)
2008. 04.28.2008. Sr Research Chemi
2008. 06.12.2008. TransPharma
2008. 08.11.2008. R&D ReStructuring
2008. 09.08.2008. AD R&D Team
2008. 10.03.2008. Deciphera Pharma
2008. 10.07.2008. Tuberculosis
2008. 10.13.2008. CEO
2008. 10.13.2008. CFO
2008. 10.20.2008. Diabetes Glu.
2008. 10.20.2008. VP Endocrine & CV
2008. 11.03.2008. CN>R&D Coord.
2008. 11.03.2008. VP>Discovery
2008. 11.03.2008. VP>R&D Global
2008. 11.17.2008. PharmacoGenetics
2009. 03.09.2009. CN>Head
2009. 05.25.2009. Discovery IT
2009. 06.22.2009. VP Discov. Chem.
2009. 10.14.2009. Evonik
2009. 12.21.2009. Incyte Pharma.
2010. 02.23.2010. Asian Cancer
2010. 03.26.2010. Thermo Fisher
2010. 07.20.2010. Alnara Pharma.
2010. 08.17.2010. AD>Semagacestat
2010. 11.02.2010. Diabetes>CN
2011. 04.26.2011. Neuro.>PD
2012. 05.22.2012. Diabetes Dul.
2012. 06.04.2012. BoD
2012. 06.04.2012. Onco.>Lung C. P
2012. 06.12.2012. CN>Novast Labs.
2012. 07.06.2012. Neuro.>Pediatrics
2012. 07.22.2012. CV.>HyperCholest.
2012. 08.07.2012. Osteoporosis
2012. 08.09.2012. Amylin Payment
2012. 08.17.2012. Diabetes Lin.
2012. 08.24.2012. Patent Validity
2012. 08.29.2012. Neuro.>Schizophr
2012. 08.31.2012. Sr VP &
2012. 09.04.2012. Diab. 1 Mobile A.
2012. 10.30.2012. Chief Ethics &
2012. 10.30.2012. Uro.>BPH
2012. 12.12.2012. Neuro.>AD
2013. 01.07. Diab.>Basal Insuli>LYS
2013. 01.15.2013. Neuro.>AD>Diag.
2013. 02.07.2013. Rheuma.>RA>T
2013. 04.02.2013. Insulin Mfg. Oper
2013. 04.17.2013. Neuro.>AD>Diag.
2013. 05.10.2013. Onco.>DLBCL
2013. 05.30.2013. IBRI
2013. 06.13.2013. Neuro.>AD>Treat.
2013. 06.13.2013. Rheuma.>RA>B
2013. 07.23. Rheuma.>OA
2013. 09.26. Onco.>Breast C.>R
2013. 11.14. Insulin Mfg. Capacity
2013. 12.05. Neuro.>MDD
2013. 12.17. Cancer Research UK
2014. 01.07. Financial Guidance
2014. 01.13. Migraine
2014. 02.19. Onco.>Lung C.>R
2014. 02.24. Lohmann AH Acq. By:
2014. 03.05. Diab.>Empagliflozin
2014. 04.06. Onco.>Breast C.>B
2014. 04.21. Onco.>Gastric C.>R
2014. 04.22. Acq. Novartis AH
2014. 05.14. Onco.>Lung C.>N
2014. 05.28. ED>Tadalafil>OTC
2014. 06.11. Onco.>Liver C.
2014. 07.16. ImmunoCore
2014. 08.21. Derma.>Psoriasis
2014. 09.04. Diab.>Basal Insuli>BIL
2014. 09.12. Onco.>Colon C.
2014. 09.18. Diab.>Dulaglutide
2014. 10.02. SLE>Tabalumab
2014. 10.22. Onco.>Zymeworks
2014. 12.16. Onco.>Lung C.>R+D
2015. 01.01. Novartis AH Acq.
2015. 03.19. Hanmi Pharma.
2015. 03.20. Innovent Biologics
2015. 05.11. BioNTech AG.
2015. 05.14. Sanford-Burnham
2015. 06.17. Dana-Farber Cancer
2015. 06.17. Onco.>Sarah Cannon
2015. 08.18. Diab.>Insulin Analog
2015. 08.27. Diab.>E+M
2015. 09.21. Onco.>Gastric C.>R+P
2015. 10.11. Innovent Biologics
2015. 11.24. Onco.>Lung C.>N
2015. 12.16. Diab.>Insulin Glargine
2016. 05.31. Diab.>L+M
2016. 10.19. Soft Tissue Sarcoma
2017. 02.13. Rheuma.>RA
2017. 07.06. Purdue Uni.
2017. 10.18. Onco.>CureVac
2018. 05.14. Acq. Aurka Pharma
2018. 07.24. AH. Elanco Spin-Off
2018. 08.14. Senior Notes
2018. 09.27. Migraine E USA>OK
2018. 10.29. Dicerna Pharma.
2018. 12.12. Neuro.>AD.>AC Immune
2018. 12.14. Acq. Hydra Biosciences
2019. 01.07. Acq. Loxo Oncology
2019. 01.31. Onco.>Lung C.
2019. 03.26. ImmuNext
2019. 04.22. Avidity Biosciences
2019. 05.13. Onco.>HCC
2019. 05.28. Non-Opioid Pain
2019. 06.04. Episodic Cluster Heada
2019. 07.24. Diabetes USA>OK
2019. 08.26. AS.
2019. 10.11. Migraine R USA>OK
2020. 01.10. Acq. Dermira
2020. 01.23. Diabetes CA>Launch
2020. 01.31. Migraine R USA>Launc
2020. 03.18. COVID-19 Diag.
2020. 04.10. COVID-19 Treat.
2020. 05.08. Onco.>Lung & Thyroid C
2020. 05.28. Neuro.>AD>Diag.
2020. 06.15. rapid-acting insulin
2020. 09.22. Diabetes Dulaglutide
2020. 10.15. Acq. Disarm Therapeuti
2020. 11.13. Seed Therapeutics
2020. 11.19. COVID 19>Baricitinib
2020. 11.20. COVID 19>Bamlanivimab
2020. 12.15. Acq. Prevail Therapeut
2021. 01.19. Onco.>Merus NV
2021. 01.28. Pain Drug Candidate
2021. 02.09. COVID 19>Bamlanivimab+
2021. 07.14. Acq. Protomer Tech
2021. 08.25. Lycia Therapeutics
2021. 10.13. Onco.>Breast C.
2021. 12.10. Regor Therapeutics
2021. 12.13. Foghorn Therapeutics
2022. 01.06. Entos Pharmaceuticals
2022. 02.11. COVID 19>Bebtelovimab
2022. 05.13. Endo.>Diab. 2>USA>OK
2022. 06.13. Derma.>AA
2022. 10.18. Acq. Akouos Inc
2022. 12.01. Acq. Akouos Inc
2023. 01.27. Onco.>MCL>USA>OK
2023. 06.20. Acq. Dice Alpha Inc
2023. 06.29. Acq. Sigilon Therapeut
2023. 07.14. Acq. Versanis
2023. 08.09. Acq. Dice Alpha Inc
2023. 08.14. Acq. Sigilon Therapeut
2023. 08.14. Acq. Versanis
2023. 10.03. Acq. POINT Biopharma
2023. 10.18. Acq. Mablink Bioscienc
2023. 10.26. Gastro.>UC>USA>OK
2023. 12.27. Acq. POINT Biopharma
About>Partner>Profiles C2
CardioVascular Therapeutic Tec/P
Chorus Div. C2
Devices for Vascular Intervention/P
Elanco Animal Health Div C2
InnoCentive
Lilly Asia Ventures. C2
Lilly Ventures C2
Patents
Web-Site
Z - OK
Eli Lilly./P C2's products
This section has no products